Financial Data and Key Metrics Changes - For Q4 2025, reported sales increased by 14% to $963 million, up from $848 million in the prior year, while core sales grew by 5% [3][4] - Full-year reported sales rose by 5% to $3.8 billion, compared to $3.6 billion in the previous year, with core sales up by 2% [5][24] - Reported net income increased by 5% to $393 million, and reported earnings per share grew by 7% to $5.89, up from $5.53 a year ago [5][24] - Adjusted earnings per share were $5.74, a slight decline of 1% compared to the prior year [6][24] - Adjusted EBITDA margin for Q4 was approximately 19.8%, down from 23% in the prior year [17][24] Business Line Data and Key Metrics Changes - Pharma segment core sales increased by 4%, with prescription core sales up by 1% and consumer healthcare core sales up by 3% [17][18] - Injectables core sales surged by 24%, driven by strong demand for elastomeric components [18] - Beauty segment core sales increased by 10%, with personal care core sales rising by 17% [19][20] - Closures segment core sales increased by 1%, with beverage core sales up by 7% [21] Market Data and Key Metrics Changes - Strong demand was noted in the pharma segment, particularly for systemic nasal drug delivery and injectables [4][8] - The beauty segment experienced double-digit growth across fragrance and facial skincare markets [4][19] - The closures segment saw volume growth, although impacted by lower resin pricing [21] Company Strategy and Development Direction - The company is focusing on cost reduction initiatives and back-office centralization through global talent centers [4][29] - There is an emphasis on productivity measures and efficiency improvements, with expectations for continued growth in the pharma segment excluding emergency medicine [30][28] - The company aims to maintain a disciplined approach to capital allocation while investing in long-term growth opportunities [6][25] Management's Comments on Operating Environment and Future Outlook - Management anticipates near-term headwinds in emergency medicine extending through 2026, with a revenue headwind of approximately $65 million expected [26] - The company expects steady improvements in beauty margins and overall performance in the second half of 2026 [34][39] - There is confidence in the growth potential of the pharma segment, particularly in injectables and systemic nasal drug delivery technologies [30][45] Other Important Information - The company returned $486 million to shareholders in 2025 through share repurchases and dividends, marking its 32nd consecutive year of increasing dividends [6][25] - The company issued $600 million of senior notes in Q4 2025 to support its capital structure [23] Q&A Session Summary Question: Is there any deceleration in GLP-1 demand in elastomers in 2026? - Management expects injectables to grow in the high single digits to low double digits, with GLP-1 being an important but not sole driver of growth [32][33] Question: What is the expectation for EBITDA margin trends throughout the year? - Margins are expected to improve significantly in the second half of the year, driven by increased volume and productivity measures [34] Question: Can you elaborate on the margin performance in beauty and closures? - Operational issues and environmental upgrades impacted margins, but improvements are expected as these issues are resolved [39][40] Question: What is the outlook for emergency medicine sales? - Emergency medicine is expected to face challenges, with a significant decline anticipated in the first half of 2026 [26][41] Question: How does the company view the growth potential for Narcan and cough and cold products? - Management sees low to mid-single-digit growth for Narcan and anticipates a strong cough and cold season, with updates expected in Q1 and Q2 [46][48]